4 research outputs found
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a cause of heart failure in the elderly.
Although wild-type transthyretin amyloidosis is the most frequent form of ATTR-CM found in the elderly, hereditary
transthyretin amyloidosis (ATTRv) can also occur. We sought to determine the prevalence of ATTRv among elderly
ATTR-CM patients, identify predictors of ATTRv and evaluate the clinical consequences of positive genetic testing in
this population. Prevalence of ATTRv in elderly ATTR-CM patients (â„70 years) was assessed in a cohort of 300 consecutive ATTR-CM
patients (median age 78 years at diagnosis, 82% â„70 years, 16% female, 99% Caucasian). ATTRv was diagnosed in
35 (12%; 95% confidence interval [CI] 3.1â8.8) and 13 (5.3%; 95% CI 5.6â26.7) patients in the overall cohort
and in those â„70 years, respectively. Prevalence of ATTRv among elderly female patients with ATTR-CM was
13% (95% CI 2.1â23.5). Univariate analysis identified female sex (odds ratio [OR] 3.66; 95% CI 1.13â11.85;
p = 0.03), black ancestry (OR 46.31; 95% CI 3.52âInf; p = 0.005), eye symptoms (OR 6.64; 95% CI 1.20â36.73;
p = 0.03) and polyneuropathy (OR 10.05; 95% CI 3.09â32.64; p<0.001) as the only factors associated with ATTRv
in this population. Diagnosis of ATTRv in elderly ATTR-CM patients allowed initiation of transthyretin-specific
drug treatment in 5 individuals, genetic screening in 33 relatives from 13 families, and identification of 9 ATTRv
asymptomatic carriers. Hereditary transthyretin amyloidosis is present in a substantial number of ATTR-CM patients aged â„70 years.
Identification of ATTRv in elderly patients with ATTR-CM has clinical meaningful therapeutic and diagnostic
implications. These results support routine genetic testing in patients with ATTR-CM regardless of ageThis study has been funded by Instituto de Salud Carlos III (ISCIII)
through the projects âPI18/0765 & PI20/01379â (co-funded by
European Regional Development Fund/European Social Fund âA
way to make Europeâ/âInvesting in your futureâ). AMB receives grant
support by ISCIII (CM20/002209). The CNIC is supported by the
ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa
grant (CEX2020-001041-S
Mechanical circulatory support in severe primary graft dysfunction: peripheral cannulation but not earlier implantation improves survival in heart transplantation
[Abstract] Background. Primary graft dysfunction (PGD) still affects 2-28% of heart transplants (HT). Severe PGD requires mechanical circulatory support (MCS) and is the main cause of death early after HT. Earlier initiation has been suggested to improve prognosis but the best cannulation strategy is unknown.
Methods. Analysis of all HT in Spain between 2010 and 2020. Early (<3 hours after HT) vs late initiation (â„3 hours after HT) of MCS was compared. Special focus was placed on peripheral vs central cannulation strategy.
Results. 2376 HT were analyzed. 242 (10.2%) suffered severe PGD. 171 (70.7%) received early MCS and 71 (29.3%) late MCS. Baseline characteristics were similar. Patients with late MCS had higher inotropic scores and worse renal function at the moment of cannulation. Early MCS had longer cardiopulmonary bypass times and late MCS was associated with more peripheral vascular damage. No significant differences in survival were observed between early and late implant at 3 months (43.82% vs 48.26%; log-rank p=0.59) or at 1 year (39.29% vs 45.24%, log-rank p=0.49). Multivariate analysis did not show significant differences favoring early implant. Survival was higher in peripheral compared to central cannulation at 3 months (52.74% vs. 32.42%, log-rank p 0.001) and one year (48.56% vs. 28.19%, log-rank p 0.0007). In the multivariate analysis, peripheral cannulation remained a protective factor.
Conclusions. Earlier MCS initiation for PGD was not superior compared to a more conservative approach with deferred initiation. Peripheral compared to central cannulation showed superior 3-month and 1-year survival rates